Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke

JAMA

Volumn 309, Issue 23, 2013, Pages 2480-2488

  Saver, Jeffrey L ^a   Fonarow, Gregg C ^a   Smith, Eric E ^b   Reeves, Mathew J ^c   Grau Sepulveda, Maria V ^d   Pan, Wenqin ^d   Olson, DaiWai M ^d,f   Hernandez, Adrian F ^d   Peterson, Eric D ^d   Schwamm, Lee H ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

AGED; ARTICLE; BRAIN HEMATOMA; BRAIN ISCHEMIA; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; MORTALITY; ONSET TO TREATMNET TIME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION; UNITED STATES;

EID: 84879069684     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.6959     Document Type: Article

References (31)

1. Adams HP Jr, del Zoppo G, Alberts MJ, et al American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Guidelines for the early management of adults with ischemic stroke. Stroke. 2007;38(5):1655-1711. (Pubitemid 46691097)
2. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke. Lancet. 2012;379(9834):2364-2372.
3. Meng X, Fisher M, Shen Q, Sotak CH, Duong TQ. Characterizing the diffusion/perfusion mismatch in experimental focal cerebral ischemia. Ann Neurol. 2004;55(2):207-212. (Pubitemid 38166997)
4. Saver JL. Time is brain - quantified. Stroke. 2006;37(1):263-266. (Pubitemid 43732089)
5. Lees KR, Bluhmki E, von Kummer R, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke. Lancet. 2010;375(9727):1695-1703.
6. Saver JL, Levine SR. Alteplase for ischaemic stroke - much sooner is much better. Lancet. 2010;375(9727):1667-1668.
7. Strbian D, Soinne L, Sairanen T, et al Helsinki Stroke Thrombolysis Registry Group. Ultraearly thrombolysis in acute ischemic stroke is associated with better outcome and lower mortality. Stroke. 2010;41(4):712-716.
8. Saposnik G, Di Legge S, Webster F, Hachinski V. Predictors of major neurologic improvement after thrombolysis in acute stroke. Neurology. 2005;65(8):1169-1174. (Pubitemid 41508205)
9. Sobesky J, Frackowiak M, Zaro Weber O, et al. The Cologne stroke experience: safety and outcome in 450 patients treated with intravenous thrombolysis. Cerebrovasc Dis. 2007;24(1):56-65. (Pubitemid 47026142)
10. LaBresh KA, Reeves MJ, Frankel MR, Albright D, Schwamm LH. Hospital treatment of patients with ischemic stroke or transient ischemic attack using the "Get With The Guidelines" program. Arch Intern Med. 2008;168(4):411-417. (Pubitemid 351347133)
11. Schwamm LH, Fonarow GC, Reeves MJ, et al. Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation. 2009;119(1):107-115.
12. Saver JL, Gornbein J, Grotta J, et al. Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window. Stroke. 2009;40(7):2433-2437.
13. Lansberg MG, Schrooten M, Bluhmki E, Thijs VN, Saver JL. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale. Stroke. 2009;40(6):2079-2084.
14. Mazya M, Egido JA, Ford GA, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase. Stroke. 2012;43(6):1524-1531.
15. Fonarow GC, Smith EE, Saver JL, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke. Circulation. 2011;123(7):750-758.
16. Fonarow GC, Saver JL, Smith EE, et al. Relationship of National Institutes of Health Stroke Scale to 30-day mortality in Medicare beneficiaries with acute ischemic stroke. J Am Heart Assoc. 2012;1(1):42-50.
17. Hodgson C, Lindsay P, Rubini F. Can mass media influence emergency department visits for stroke? Stroke. 2007;38(7):2115-2122. (Pubitemid 47012277)
18. Robinson TG, Reid A, Haunton VJ, Wilson A, Naylor AR. The face arm speech test: does it encourage rapid recognition of important stroke warning symptoms [published online ahead of print July 4, 2012]? Emerg Med J. 2012;30(6):467-471.
19. Morgenstern LB, Gonzales NR, Maddox KE, et al. A randomized, controlled trial to teach middle school children to recognize stroke and call 911. Stroke. 2007;38(11):2972-2978.
20. Boden-Albala B, Stillman J, Perez T, et al. A stroke preparedness RCT in a multi-ethnic cohort. Contemp Clin Trials. 2010;31(3):235-241.
21. Acker JE III, Pancioli AM, Crocco TJ, et al. Implementation strategies for emergency medical services within stroke systems of care. Stroke. 2007;38(11):3097-3115.
22. Schwamm LH, Pancioli A, Acker JE III, et al American Stroke Association's Task Force on the Development of Stroke Systems. Recommendations for the establishment of stroke systems of care. Stroke. 2005;36(3):690-703.
23. Lin CB, Peterson ED, Smith EE, et al. Emergency medical service hospital prenotification is associated with improved evaluation and treatment of acute ischemic stroke. Circ Cardiovasc Qual Outcomes. 2012;5(4):514-522.
24. A systems approach to immediate evaluation and management of hyperacute stroke. Stroke. 1997;28(8):1530-1540.
25. Tveiten A, Mygland A, Ljøstad U, Thomassen L. Intravenous thrombolysis for ischaemic stroke: short delays and high community-based treatment rates after organisational changes in a previously inexperienced centre. Emerg Med J. 2009;26(5):324-326.
26. Köhrmann M, Schellinger PD, Breuer L, et al. Avoiding in hospital delays and eliminating the three-hour effect in thrombolysis for stroke. Int J Stroke. 2011;6(6):493-497.
27. Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology. 2012;79(4):306-313.
28. Xian Y, Fonarow GC, Reeves MJ, et al. Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke). Am Heart J. 2012;163(3):392-398.
29. Reeves MJ, Fonarow GC, Smith EE, et al. Representativeness of the Get With The Guidelines-Stroke Registry: comparison of patient and hospital characteristics among Medicare beneficiaries hospitalized with ischemic stroke. Stroke. 2012;43(1):44-49.
30. Ovbiagele B, Saver JL. Day-90 acute ischemic stroke outcomes can be derived from early functional activity level. Cerebrovasc Dis. 2010;29(1):50-56.
31. Zhang Q, Saver JL. The relation between destination on hospital discharge and final 3 month disability outcome in acute ischemic stroke. Stroke. 2013;44:ATP379. http://stroke.ahajournals.org/cgi/content/meeting-abstract/44/2- MeetingAbstracts/ATP379. Accessed May 31, 2013. Neurological Disorders and Stroke